Navigation Links
Novartis Drug Diovan Shows Superior Benefits

Results of a Japanese study have given drug giant Novartis AG, more reasons to smile. According to the study published in The Lancet, the company’s blood pressure// drug Diovan was observed to reduce the risks of strokes and cardiovascular events by up to 40 percent.

The study titled the Jikei Heart Study, was based on 3,000 people aged 20 to 79, with high blood pressure, ischemic heart disease or congestive heart failure. The study which was published recently in The Lancet, showed that Diovan produced a 39 percent reduction in cardiovascular events and a 40 percent cut in strokes.

The study compared Diovan when added to a conventional non-angiotensin receptor blocker (ARB) versus the non-ARB therapy alone. Accordingly, the superior benefits reported with Diovan led to an early termination of the study.

In addition to its impact on overall cardiovascular events and stroke, other benefits of Diovan demonstrated were: relative reductions of 65 percent in angina pectoris, 46 percent in heart failure and 81 percent in aortic dissection - separation of the wall layers in the body's main artery – as compared to other treatment groups.

There were few adverse events (2.5 percent overall) with no significant difference in tolerability between the groups. According to investigators, these effects were reported independently of blood pressure reductions.

Says Gordon McInnes, Professor of Medicine at the Western Infirmary in Glasgow, Scotland:"The results of this trial carry an important clinical message for physicians across the globe who are trying to protect patients from debilitating complications such as stroke. "Jikei Heart tells us that adding Diovan to usual treatment regimens can offer substantial long-term protection”, he added.

The Jikei Heart Study is the first controlled trial to assess the cardiovascular benefits of adding the angiotensin receptor blocker, or ARB, Diovan to conventional non-A
'"/>




Page: 1 2

Related medicine news :

1. Novartis files application with FDA for Zometa
2. Canine Painkiller unveiled by Novartis
3. Glivec the hot cancer drug from Novartis
4. Zometa [Novartis Drug] For Treatment Of Paget’s Diseas
5. Novartis MS Drug Shows Promising Results
6. Bird-flu Vaccine Adjuvant Contract Goes to Novartis
7. Drop Patent Petition, Activists Ask Novartis
8. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
9. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
10. Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors
11. Experimental treatment for Ebola Virus Shows promising results in mice
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Novartis Drug Diovan Shows Superior Benefits

(Date:9/18/2014)... It is that time of year – ... Once again, Evensong Spa at Heidel House ... services at a special $50 rate Oct. 20 through Nov. ... Hotels & Resorts , is the only Wisconsin destination spa ... embrace health and wellness by experiencing affordable spa and wellness ...
(Date:9/18/2014)... Study after study has proven it true: exercise is ... Pennsylvania scientists suggests that exercise may have an added ... performed in a mouse model of melanoma, found that ... alone. , Joseph Libonati, an associate professor in ... of Innovative and Translational Nursing Research, was the senior ...
(Date:9/18/2014)... Lake City, UT (PRWEB) September 18, 2014 ... North America will be recognizing their shared fundraising impact ... on Thursday, Sept. 25. , The first-ever Dance Marathon ... more than $20 million projected to be raised by ... their community’s CMN Hospital. Donations generated through Dance Marathon ...
(Date:9/18/2014)... -- don,t worry, it,s a good thing! As scientists ... are bad. Many active enzymes and bacteria are merely ... an important part of our digestive system or can ... , an opportunistic yeast pathogen and model organism for ... personal ecosystem. However, when our immune system is stressed ...
(Date:9/18/2014)... ANGELES (September 18, 2014) The National Institutes ... funding from a four-year, $1.3 million grant to the ... in the research and development of a vaccine to ... and Methicillin-resistant Staphylococcus aureus (MRSA). , ... of the NIH awarded the grant to LA BioMed ...
Breaking Medicine News(10 mins):Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... Use of anesthesia providers to monitor sedation during screening ... from 2003 to 2009 in the United States, with ... not need this service, according to a new RAND ... as $1.1 billion spent annually on anesthesia services for ...
... March 20 (HealthDay News) -- Calculating the difference ... right arms might help predict a patient,s odds of ... Researchers found that people with high blood pressure whose ... higher risk of cardiovascular death over 10 years. ...
... (HealthDay News) -- The northeastern United States may see a significant ... The reason is that oak trees produced relatively few acorns ... years for the acorn crop. But the small crop means trouble ... had a boom in acorns, followed by a boom in mice. ...
... Reporter , TUESDAY, March 20 (HealthDay News) -- ... own stem cells may someday replace or reduce the ... Six months after receiving a kidney transplant, only ... stem cells experienced rejection compared with almost 22 percent ...
... failure and endocrine tumors are among the suspects causing ... relievers in your medicine cabinet be the culprit? ... Sackler Faculty of Medicine and the Sheba Medical Center, ... of hypertension, which is a major risk factor for ...
... March 20 (HealthDay News) -- Seeing a baby,s face triggers ... reward and planning movement, a finding researchers say may indicate ... Researchers observed this pattern in adults who didn,t know the ... "These adults have no children of their own. Yet images ...
Cached Medicine News:Health News:Use of anesthesia providers during GI procedures is growing, but may be unnecessary 2Health News:Blood Pressure Variance Between Arms Points to Heart Risk 2Health News:Northeast U.S. Should Brace for Spike in Lyme Disease: Expert 2Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 2Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 3Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 4Health News:Pain relievers could be spiking your blood pressure 2Health News:Infants' Faces Trigger Caregiving Impulse in Adults' Brains 2
(Date:9/18/2014)... , Sept. 18, 2014  Iliad Neurosciences, Inc., ... to diagnosing and treating Autism Spectrum Disorders (ASD) announced ... Agreement with The Research Foundation for The State University ... will provide a new biomarker to identify an abnormality ... to ASD. This biomarker is expected to be available ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
(Date:9/18/2014)... YORK and PLAINSBORO, N.J. ... announced today its support of the National Hemophilia ... Care , which provides support to people with ... physical and psychosocial challenges that can impede disease ... six modules, Communication With Your Provider About ...
Breaking Medicine Technology:Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... in patients with non-small cell lung cancer has ... multi-center, monotherapy,study of KOS-1584 in patients with measurable ... previously received only one prior,chemotherapy regimen. The primary ...
... SAN DIEGO, April 13 Researchers from ... today presented findings,showing that adding curcumin or ... preventing the growth of chemo-resistant colon cancer,cells. ... American Association,for Cancer Research (AACR) Annual Meeting ...
Cached Medicine Technology:Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 2Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 3Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 4Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2
... Flexible biopsy forceps are extremely delicate ... incompetent repair source, they can easily be ... turn, damage your endoscopes. , On the ... flexible biopsy forceps can have a virtually ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
... With our factory-quality repairs, physicians know ... why more hospitals turn to Mobile Instrument ... We offer a full line of carbide ... our four-way quality control process. You'll enjoy ...
Inquire...
Medicine Products: